Stockreport

Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF at 24 weeks and consistent anti-fibrotic signals at 48 weeks; the pivotal study will be three-arm (placebo, 1.8 mg [powered], 2.4 mg) and will use AIM-MASH AI Assist to [Read more]